View in EDS PDF Full Text

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Saved in:
Bibliographic Details
Title: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Authors: Powles, Thomas, Eder, Joseph Paul, Petrylak, Daniel P., Fine, Gregg D., Teng, Siew-leng, Shen, Xiaodong, Boyd, Zachary, Hegde, Priti S., Chen, Daniel S., Braiteh, Fadi S., Loriot, Yohann, Cruz, Cristina, Bellmunt, Joaquim, Burris, Howard A., Vogelzang, Nicholas J.
Source: Nature. 11/27/2014, Vol. 515 Issue 7528, p558-562. 5p.
Subjects: Metastasis, Bladder cancer treatment, Cancer chemotherapy, Somatic mutation, Antigens
Abstract: There have been no major advances for the treatment of metastatic urothelial bladder cancer (UBC) in the last 30 years. Chemotherapy is still the standard of care. Patient outcomes, especially for those in whom chemotherapy is not effective or is poorly tolerated, remain poor. One hallmark of UBC is the presence of high rates of somatic mutations. These alterations may enhance the ability of the host immune system to recognize tumour cells as foreign owing to an increased number of antigens. However, these cancers may also elude immune surveillance and eradication through the expression of programmed death-ligand 1 (PD-L1; also called CD274 or B7-H1) in the tumour microenvironment. Therefore, we examined the anti-PD-L1 antibody MPDL3280A, a systemic cancer immunotherapy, for the treatment of metastatic UBC. MPDL3280A is a high-affinity engineered human anti-PD-L1 monoclonal immunoglobulin-G1 antibody that inhibits the interaction of PD-L1 with PD-1 (PDCD1) and B7.1 (CD80). Because PD-L1 is expressed on activated T cells, MPDL3280A was engineered with a modification in the Fc domain that eliminates antibody-dependent cellular cytotoxicity at clinically relevant doses to prevent the depletion of T cells expressing PD-L1. Here we show that MPDL3280A has noteworthy activity in metastatic UBC. Responses were often rapid, with many occurring at the time of the first response assessment (6 weeks) and nearly all were ongoing at the data cutoff. This phase I expansion study, with an adaptive design that allowed for biomarker-positive enriched cohorts, demonstrated that tumours expressing PD-L1-positive tumour-infiltrating immune cells had particularly high response rates. Moreover, owing to the favourable toxicity profile, including a lack of renal toxicity, patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy. These results suggest that MPDL3280A may have an important role in treating UBC-the drug received breakthrough designation status by the US Food and Drug Administration (FDA) in June 2014. [ABSTRACT FROM AUTHOR]
Copyright of Nature is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 99713989
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Powles%2C+Thomas%22">Powles, Thomas</searchLink><br /><searchLink fieldCode="AR" term="%22Eder%2C+Joseph+Paul%22">Eder, Joseph Paul</searchLink><br /><searchLink fieldCode="AR" term="%22Petrylak%2C+Daniel+P%2E%22">Petrylak, Daniel P.</searchLink><br /><searchLink fieldCode="AR" term="%22Fine%2C+Gregg+D%2E%22">Fine, Gregg D.</searchLink><br /><searchLink fieldCode="AR" term="%22Teng%2C+Siew-leng%22">Teng, Siew-leng</searchLink><br /><searchLink fieldCode="AR" term="%22Shen%2C+Xiaodong%22">Shen, Xiaodong</searchLink><br /><searchLink fieldCode="AR" term="%22Boyd%2C+Zachary%22">Boyd, Zachary</searchLink><br /><searchLink fieldCode="AR" term="%22Hegde%2C+Priti+S%2E%22">Hegde, Priti S.</searchLink><br /><searchLink fieldCode="AR" term="%22Chen%2C+Daniel+S%2E%22">Chen, Daniel S.</searchLink><br /><searchLink fieldCode="AR" term="%22Braiteh%2C+Fadi+S%2E%22">Braiteh, Fadi S.</searchLink><br /><searchLink fieldCode="AR" term="%22Loriot%2C+Yohann%22">Loriot, Yohann</searchLink><br /><searchLink fieldCode="AR" term="%22Cruz%2C+Cristina%22">Cruz, Cristina</searchLink><br /><searchLink fieldCode="AR" term="%22Bellmunt%2C+Joaquim%22">Bellmunt, Joaquim</searchLink><br /><searchLink fieldCode="AR" term="%22Burris%2C+Howard+A%2E%22">Burris, Howard A.</searchLink><br /><searchLink fieldCode="AR" term="%22Vogelzang%2C+Nicholas+J%2E%22">Vogelzang, Nicholas J.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Nature%22">Nature</searchLink>. 11/27/2014, Vol. 515 Issue 7528, p558-562. 5p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Metastasis%22">Metastasis</searchLink><br /><searchLink fieldCode="DE" term="%22Bladder+cancer+treatment%22">Bladder cancer treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+chemotherapy%22">Cancer chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Somatic+mutation%22">Somatic mutation</searchLink><br /><searchLink fieldCode="DE" term="%22Antigens%22">Antigens</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: There have been no major advances for the treatment of metastatic urothelial bladder cancer (UBC) in the last 30 years. Chemotherapy is still the standard of care. Patient outcomes, especially for those in whom chemotherapy is not effective or is poorly tolerated, remain poor. One hallmark of UBC is the presence of high rates of somatic mutations. These alterations may enhance the ability of the host immune system to recognize tumour cells as foreign owing to an increased number of antigens. However, these cancers may also elude immune surveillance and eradication through the expression of programmed death-ligand 1 (PD-L1; also called CD274 or B7-H1) in the tumour microenvironment. Therefore, we examined the anti-PD-L1 antibody MPDL3280A, a systemic cancer immunotherapy, for the treatment of metastatic UBC. MPDL3280A is a high-affinity engineered human anti-PD-L1 monoclonal immunoglobulin-G1 antibody that inhibits the interaction of PD-L1 with PD-1 (PDCD1) and B7.1 (CD80). Because PD-L1 is expressed on activated T cells, MPDL3280A was engineered with a modification in the Fc domain that eliminates antibody-dependent cellular cytotoxicity at clinically relevant doses to prevent the depletion of T cells expressing PD-L1. Here we show that MPDL3280A has noteworthy activity in metastatic UBC. Responses were often rapid, with many occurring at the time of the first response assessment (6 weeks) and nearly all were ongoing at the data cutoff. This phase I expansion study, with an adaptive design that allowed for biomarker-positive enriched cohorts, demonstrated that tumours expressing PD-L1-positive tumour-infiltrating immune cells had particularly high response rates. Moreover, owing to the favourable toxicity profile, including a lack of renal toxicity, patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy. These results suggest that MPDL3280A may have an important role in treating UBC-the drug received breakthrough designation status by the US Food and Drug Administration (FDA) in June 2014. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Nature is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=99713989
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/nature13904
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 558
    Subjects:
      – SubjectFull: Metastasis
        Type: general
      – SubjectFull: Bladder cancer treatment
        Type: general
      – SubjectFull: Cancer chemotherapy
        Type: general
      – SubjectFull: Somatic mutation
        Type: general
      – SubjectFull: Antigens
        Type: general
    Titles:
      – TitleFull: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Powles, Thomas
      – PersonEntity:
          Name:
            NameFull: Eder, Joseph Paul
      – PersonEntity:
          Name:
            NameFull: Petrylak, Daniel P.
      – PersonEntity:
          Name:
            NameFull: Fine, Gregg D.
      – PersonEntity:
          Name:
            NameFull: Teng, Siew-leng
      – PersonEntity:
          Name:
            NameFull: Shen, Xiaodong
      – PersonEntity:
          Name:
            NameFull: Boyd, Zachary
      – PersonEntity:
          Name:
            NameFull: Hegde, Priti S.
      – PersonEntity:
          Name:
            NameFull: Chen, Daniel S.
      – PersonEntity:
          Name:
            NameFull: Braiteh, Fadi S.
      – PersonEntity:
          Name:
            NameFull: Loriot, Yohann
      – PersonEntity:
          Name:
            NameFull: Cruz, Cristina
      – PersonEntity:
          Name:
            NameFull: Bellmunt, Joaquim
      – PersonEntity:
          Name:
            NameFull: Burris, Howard A.
      – PersonEntity:
          Name:
            NameFull: Vogelzang, Nicholas J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 11
              Text: 11/27/2014
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-print
              Value: 00280836
          Numbering:
            – Type: volume
              Value: 515
            – Type: issue
              Value: 7528
          Titles:
            – TitleFull: Nature
              Type: main
ResultId 1